thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
==== Germany ==== DET is controlled in Germany under Anlage I BtMG (Narcotics Act, Schedule I). as of January 24, 1974. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
== Other abbreviating conventions == In some health care institutions, house rules deprecate the standard symbol for microgram, "μg", in prescribing or chart recording, because of the risk of giving an incorrect dose because of the misreading of poor handwriting. The two alternatives are to abbreviate as "mcg" or to write out "microgram" in full (see also List of abbreviations used in medical prescriptions). The alternative abbreviation may be ambiguous in rare circumstances in that mcg could also be read as a micrigram, i.e. 10−14 g; however the prefix micri is not standard, nor widely known, and is considered obsolete. This deprecation, focused on avoiding incorrect dosing in contexts where handwriting is often present, does not extend to all health-care contexts and institutions (for example, some clinical laboratories' reports adhere to it, whereas others do not), and in physical sciences research, "μg" remains the sole official abbreviation. In medical data exchange according to the Health Level 7 (HL7) standard, the μ can be replaced by u as well.
Thermal ionization (also known as surface ionization, or contact ionization) involves spraying vaporized, neutral atoms onto a hot surface, from which the atoms re-evaporate in ionic form. To generate positive ions, the atomic species should have a low ionization energy, and the surface should have a high work function. This technique is most suitable for alkali atoms (Li, Na, K, Rb, Cs) which have low ionization energies and are easily evaporated. To generate negative ions, the atomic species should have a high electron affinity, and the surface should have a low work function. This second approach is most suited for halogen atoms Cl, Br, I, At.
== Adverse effects == More serious side effects of Mobocertinib may include agitation, bloating of the eyes, lips, feet, blurred vision, coma, decreased urine output, headache, hostility, diarrhea, depression, dizziness, fainting, lethargy, anxiety, nausea, seizures, weight gain, fatigue as well as edema. Other side effects which may be less frequent are: chills, cough, dilated neck veins, ill-feeling and trouble with breathing. Other notable side effects of taking Mobocertinib are: having an acidic stomach, heartburn, acidity, hair loss/thinning, bone pain, sore throat, stuffy nose, trouble swallowing, vomiting and weakness in hands and feet.
=== Hormone replacement therapy === The doses of hormone replacement therapy (HRT) for CAIS individuals are debatable. Some have hypothesized that supraphysiological levels of estrogen may reduce the diminished bone mineral density associated with CAIS, while counter-arguments suggested a lower dose of HRT because levels of estrogen in CAIS individuals are normally below the female range before gonadectomy. Data has been published that suggests affected women who were not compliant with estrogen replacement therapy, or who had a lapse in estrogen replacement, experienced a more significant loss of bone mineral density. Progestin replacement therapy is usually seldom initiated as well. Androgen replacement has been reported to increase a sense of well-being in gonadectomized people with CAIS, although the mechanism by which this benefit is achieved is not well understood.
Sources: en.wikipedia.org
Inorganic chemistry has greatly benefited from qualitative theories. Such theories are easier to learn as they require little background in quantum theory. Within main group compounds, VSEPR theory powerfully predicts, or at least rationalizes, the structures of main group compounds, such as an explanation for why NH3 is pyramidal whereas ClF3 is T-shaped. For the transition metals, crystal field theory allows one to understand the magnetism of many simple complexes, such as why [FeIII(CN)6]3− has only one unpaired electron, whereas [FeIII(H2O)6]3+ has five. A particularly powerful qualitative approach to assessing the structure and reactivity begins with classifying molecules according to electron counting, focusing on the numbers of valence electrons, usually at the central atom in a molecule.
Winning Spanish American independence also involved civil war. The creation of juntas in Spanish America, such as the Junta Suprema de Caracas on 19 April 1810, set the stage for the fighting that would afflict the region for the next decade and a half. Political fault lines appeared, and were often the causes of military conflict. On the one hand the juntas challenged the authority of all royal officials, whether they recognized the Regency or not. On the other hand, royal officials and Spanish Americans who desired to keep the empire together were split between liberals, who supported the efforts of the Cortes, and conservatives (often called "absolutists" in the historiography), who did not want to see any innovations in government. Finally, although the juntas claimed to carry out their actions in the name of the deposed king, Ferdinand VII, their creation provided an opportunity for people who favored outright independence to promote their agenda publicly and safely. The proponents of independence called themselves Patriots, a term which eventually was generally applied to them. The idea that independence was not the initial concern is evidenced by the fact that few areas declared independence in the years after 1810. The congresses of Venezuela and New Granada did so in 1811 and also Paraguay in the same year (14 and 15 May 1811).
=== Psychiatry === Acetylcysteine has been studied for major psychiatric disorders, including bipolar disorder, major depressive disorder, and schizophrenia. Preliminary research indicates N-acetylcysteine may be useful in treating obsessive-compulsive disorder, specific drug addictions (cocaine), drug-induced neuropathy, trichotillomania, excoriation disorder, and a certain form of epilepsy (progressive myoclonic). Other research has tested N-acetylcysteine in anxiety disorder, attention deficit hyperactivity disorder and mild traumatic brain injury, although its efficacy for these conditions remains unestablished.
=== Efficacy of abrocitinib in treating atopic dermatitis === According to the latest meta-analysis in 2023, abrocitinib is both efficient and safe in treating moderate-to-severe AD in adolescents and adults. It also relieves itching rapidly and alleviates symptoms of AD. Abrocitinib gives significantly better results than the placebo at both 100 mg and 200 mg. The severity of AD is quantified through Eczema Area and Severity Index (EASI), which is based on the severity of lesion clinical signs. Abrocitinib was more effective than placebo in terms of EASI-reduction, but it also decreased other symptoms. The improvement of depression and anxiety was better in the experimental group than that in the control group. In another meta-analysis including 2256 patients from three different studies have shown that abrocitinib improved the EASI scores in comparison with dupilumab, even in the second week of treatment. A faster onset of Investigator's Global Assessment (IGA) response at the second week was also achieved by administering abrocitinib and early relief of itching occurred at 2 weeks. In other studies, abrocitinib (200 mg dose) achieved rapid relief from itching after four days of treatment compared with dupilumab and placebo in AD patients.
=== Upgrades === Chain Home was the primary radar system of the UK for only a short time. By 1942, many of its duties had been taken over by the far more advanced AMES Type 7 ground-controlled interception (GCI) radar systems. Whereas CH scanned an area perhaps 100 degrees wide and required considerable effort to take measurements, the Type 7 scanned the entire 360-degree area around the station, and presented it on a plan position indicator, essentially a real-time two-dimensional map of the airspace around the station. Both fighters and bombers appeared on the display, and could be distinguished using Identification friend or foe (IFF) signals. The data from this display could be read directly to the intercepting pilots, without the need for additional operators or control centres. With the deployment of GCI, CH became the early warning portion of the radar network. To further simplify operations and reduce manpower requirements, the job of plotting the targets became semi-automated. An analogue computer of some complexity, known as "The Fruit Machine", was fed information directly from the operator console, reading the goniometer setting for bearing, and the range from the setting of a dial that moved a mechanical pointer along the screen until it lay over a selected target. When a button was pushed, the Fruit Machine read the inputs and calculated the X and Y location of the target, which a single operator could then plot on a map, or relay directly over the telephone.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.